Search Results for FDA regulations

Showing 1 – 11

Trump Working on ‘New System’ to Increase Drug Competition By Zachary Brennan - Published 07 March 2017

President Donald Trump tweeted Tuesday morning that he’s “working on a new system where there will be competition in the Drug Industry,” though how such a system would work alongside the generic drug and biosimilar competitors, remains to be understood.

Categories: News, US, FDA, Drugs, Government affairs

Tags: Trump, drug prices, Cummings, Sanders, FDA regulations

Trump Criticizes ‘Slow and Burdensome’ FDA Approval Process By Zachary Brennan - Published 01 March 2017

In a joint session of Congress on Tuesday evening, President Donald Trump repeated his attacks on the US Food and Drug Administration’s (FDA) "slow and burdensome approval process," promising to "slash the restraints, not just at FDA but across our government."

Categories: News, US, FDA, Biologics and biotechnology, Drugs, Government affairs

Tags: Donald Trump, FDA regulations, Trump on FDA

Trump Targets Regulations Again With New Executive Order By Zachary Brennan - Published 27 February 2017

President Donald Trump on Friday took another swipe at federal regulations, signing an executive order that requires all federal agencies to create task forces to help “alleviate unnecessary regulatory burdens placed on the American people.”

Categories: News, US, FDA, Biologics and biotechnology, Drugs, Government affairs, Medical Devices

Tags: regulations, Trump, FDA regulations, regulatory task force

Trump’s ‘Two Out, One In’ Regulatory Policy May Apply to Some FDA Guidance By Zachary Brennan - Published 06 February 2017

The Office of Management and Budget (OMB) late last week offered guidance to federal agencies, including the US Food and Drug Administration (FDA), trying to figure out how the new “two out, one in” executive order (EO) will impact their issuance of guidance and rulemakings moving forward.

Categories: Compliance, Crisis management, Due Diligence, Ethics, Government affairs, Regulatory intelligence, Regulatory strategy

Tags: "two out, one in," Trump regulatory policy, FDA regulations

Trump Pledges to Gut FDA: Which Regulations Need to Go? By Zachary Brennan - Published 01 February 2017

With an executive order (EO) and comments from President Donald Trump yesterday calling for a massive overhaul of US Food and Drug Administration (FDA) regulations, legal experts and former FDA officials are offering some practical and creative ways the agency could clean house.

Categories: News, US, FDA, Biologics and biotechnology, Drugs, Government affairs, Regulatory intelligence, Regulatory strategy

Tags: Trump executive order on regulations, FDA regulations, FDA guidance

Trump to Pharma CEOs: 75% to 80% of FDA Regulations Will be Eliminated By Zachary Brennan - Published 31 January 2017

In a sign of what’s to come for the US Food and Drug Administration (FDA), President Donald Trump told pharmaceutical company CEOs Tuesday that his administration will be “cutting regulations at a level no one has ever seen before.”

Categories: News, US, FDA, Biologics and biotechnology, Crisis management, Drugs, Government affairs, Regulatory intelligence, Regulatory strategy

Tags: Trump, FDA regulations, pharmaceutical CEOs, Trump meeting

FDA to Issue More Guidance on 3D Printing By Zachary Brennan - Published 21 December 2016

As manufacturers use 3D printing to create devices matched to a patient’s anatomy and devices with complex internal structures, the US Food and Drug Administration (FDA) is working with universities, researchers and industry to further understand these products and issue more guidance.

Categories: News, US, FDA, Drugs, Government affairs, Medical Devices, Regulatory intelligence, Regulatory strategy

Tags: 3D printing, FDA regulations on 3D printing, 3D printed medical devices

Cancer Gene Therapies: FDA Officials Highlight Regulatory Approaches By Zachary Brennan - Published 25 November 2015

As gene therapies begin to get a foothold among other cancer treatments, the US Food and Drug Administration (FDA) is taking a more flexible, data-driven approach for preclinical testing programs for these biologically complex products, according to a new review from five FDA officials in Cancer Gene Therapy.

Categories: News, US, FDA, Biologics and biotechnology, Blood, Business Skills, Due Diligence, Human cell and tissue, Preclinical, Quality, Regulatory strategy

Tags: cancer gene therapies, CBER, FDA regulations on gene therapy, regulatory issues for CBER

FDA Reverses Long-Standing Policy of Not Publicly Posting Individuals' Comments By Zachary Brennan - Published 17 September 2015

As part of its shift to increase transparency, the US Food and Drug Administration (FDA) said on Thursday that beginning 15 October it will publicly post individuals' comments on the regulations docket.

Categories: News, US, FDA, Compliance, Government affairs, Regulatory intelligence, Regulatory strategy, Submission and registration

Tags: US FDA, regulations.gov, transparency, government affairs, online comments

FDA Planning Six New Drug, Device Regulations for 2015 By Alexander Gaffney, RAC - Published 24 November 2014

The US Food and Drug Administration (FDA) has released a list of regulations it plans to release in 2015, including six new rules set to affect pharmaceutical and medical device development.

Categories: News, US, FDA, Regulatory intelligence

Tags: Unified Agenda, Planned FDA Regulations, Proposed FDA Regulations

Six New FDA Regulations to be Introduced in 2014, Including Major Change in IND Reporting By Alexander Gaffney, RAC - Published 27 May 2014

The US Food and Drug Administration (FDA) has released an updated list of regulations it is planning to seek in 2014, known as its "Unified Agenda," outlining six new rules it says it intends to propose in 2014.

Categories: News, US, FDA, Distribution, Drugs, Manufacturing, Medical Devices

Tags: US, FDA, Unified Agenda, Proposed Rule, Regulation, Final Rule, 2014 FDA Regulations, DQSA